News
and Media


Press Releases and Media
September 21, 2023 | Press Release
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoE NEW ORLEANS and CAMBRIDGE, UK, September 21, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced …
August 8, 2023 | Press Release
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, UK, August 8, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced it will host a virtual KOL event on ‘1104, a first-in-class peptide for eosinophilic esophagitis (EoE) and allergen …
July 18, 2023 | Press Release
Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
– Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo – – Unique broad mechanistic effect across a range of key cell types associated with EoE – – Novel findings across a range of immune cells that differentiates ‘1104 from other therapies – NEW ORLEANS and CAMBRIDGE, UK, July 18, 2023 – …